Abstract:
Azido-, 4-nitro and 2,4-dinitrophenylhydrazones as well as 4,4&#39;-dihydroxybenzophenone-hydrazone and other hydrazones are disclosed which have antiestrogenic activity useful in treating estrogen-requiring tumor cells. The described hydrazones bind to estrogen receptors in the cytoplasm of tumor cells. The azido-, 4-nitro- and 2,4-dinitro-phenyl branches of the molecules appear to bind to the receptors and prevent translocation of estrogenic information into the nucleus, thereby blocking the synthesis of necessary macromolecules such as proteins. Absence of geometric isomerization from antiestrogenic to estrogenic forms of the drug minimizes estrogenic side-effects.

Description:
CROSS REFERENCE TO RELATED APPLICATION 
     This is a continuation-in-part of Applicant&#39;s copending U.S. patent application Ser. No. 685,991, filed Dec. 24, 1984, the disclosure of which is incorporated by reference. 
    
    
     BACKGROUND OF THE INVENTION 
     1. Field of the Invention 
     This invention concerns antiestrogenic compounds useful for their antineoplastic properties. 
     2. Discussion of the Background of the Invention 
     Approximately 55% of all human breast cancers are considered to be estrogen dependent. This means that these tissues contain cells that bind estrogens through an absorption and transport mechanism that allows the entry of estrogens into the cell. It is believed that estrogen receptors (which are proteins) originate in the cytoplasm of cells and initially interact with extracellular estrogens in the cell membranes to bind the estrogen to the protein receptor, as shown in FIG. 1. The protein receptor then folds on the estrogen to form a &#34;cocoon-like&#34; structure, thereby completing the tertiary structure of the receptor complex which stimulates the translocation of the receptor-estrogen complex through the pores of the nuclear membrane. The receptor protein must undergo an allosteric change in its conformation before the complex has the ability to bind to DNA. A hypothetical structure for such a tertiary estrogen-protein receptor complex which has undergone an allosteric change and assumed the &#34;cocoon-like&#34; structure is shown in FIG. 2. 
     The receptor protein must undergo this allosteric change in its conformation before the complex has the ability to bind to DNA. Once inside the nucleus, the activated receptor initiates transcription of genetic information from the DNA thereby forming m-RNA which is in turn a template for the linking of amino acids into proteins needed for cell membrane replication. 
     The antiestrogen effects produced by drugs such as tamoxifen (Nolvadex®) appear to be one of preventing the estrogen receptor from interacting with DNA in the nucleus to stimulate RNA and protein synthesis. This action initiates a block in the synthesis of macromolecules such as proteins, causing cell damage and ultimate death of the cell. 
     Antiestrogens are believed to be lipophilic molecules having a portion of the molecule which resembles naturally occurring estrogens. This portion of the antiestrogen selectively binds to the estrogen receptors. The antiestrogens, however, have a side chain arm (e.g. dimethylaminophenyl ethoxy) which distorts the three-dimensional configuration of the estrogen receptor preventing translocation of the receptor to the nucleus (see FIG. 3). A tertiary complex between chemical and receptor cannot form, thus cytoplasmic proteins which are usually synthesized in response to the translocation of the estrogen receptor are accordingly not produced, the cells are not able to replicate, and they die. Therefore, any agent that interferes with the final complex of drug and receptor ties up the receptor and prevents estrogen from entering the cells and/or blocks the DNA-RNA-protein cascade. 
     FIG. 3 shows an estrogen receptor occupied by tamoxifen wherein the dimethyl amino side chain arm prevents the receptor from forming the &#34;cocoon-like&#34; structure that was shown in FIG. 2. Prevention of this allosteric tertiary change prevents translocation of the occupied receptor to the nucleus. 
     Antiestrogens are useful in impairing growth and/or destroying estrogen dependent tumor cells because such cells require estrogen hormones for growth. 
     Tamoxifen (Nolvadex®) is a non-steroidal estrogen antagonist which is currently used in the treatment of breast cancer. The tamoxifen molecule binds to the receptor, but tamoxifen contains a dimethyl-aminophenyl ethoxy arm which apparently distorts the three-dimensional shape of the receptor molecule and inhibits the translocation of estrogenic information to the nucleus. Unfortunately, tamoxifen undergoes an isomerization under physiological conditions from the therapeutically useful trans configuration (antiestrogenic) to a cis form of the drug (estrogenic). This is a serious drawback since the antiestrogenic compound, after isomerization to an estrogenic compound, begins satisfying the estrogenic requirements of the tumor cell. In addition, the presence of an estrogen-like substance in the body results in stimulation of hypertrophy of the uterine endometrium with intermittent vaginal bleeding, especially in elderly females in whom the agent is most effective. In addition, tamoxifen is not an effective anti-cancer agent in the presence of physiological amounts of estradiol in an estrogen dependent human breast cancer cell line (ZR-75-1). 
     Most of the other available antiestrogens also have geometric centers about which trans/cis isomerization occurs. They accordingly undergo isomerization and have both estrogenic and anti-estrogenic properties. Other experimental antiestrogenic agents have the additional drawback of containing an ethyl pyrrolidine group (Lilly&#39;s Ly 156758 and Upjohns&#39; Nafoxadine) which causes allergic reactions, such as corneal ulceration, in sensitive human individuals. 
     It is an object of the present invention to provide antiestrogenic compounds which do not undergo isomerization to an estrogenic compound under physiological conditions. 
     It is another object of the present invention to provide compounds with minimum estrogenic activity which thereby reduces endometrial stimulation and hypertrophy of the uterus. 
     It is also an object of the invention to provide an antiestrogen having minimal allergic side effects. 
     SUMMARY OF THE INVENTION 
     The aforementioned objects are achieved by providing hydrazones of the following structure: 
     
                       TABLE 1______________________________________ ##STR1##NO.WHERE: R       R.sup.1                 R.sup.2     X______________________________________A-008  HO      C      CH.sub.3     C.sub.6 H.sub.32,4(NO.sub.2).sub.2A-113  HO      C      C.sub.6 H.sub.4 OH                             HA-033  H       C      C.sub.6 H.sub.5                             C.sub.6 H.sub.32,4(NO.sub.2).sub.2A-077  HO      C      C.sub.6 H.sub.4 OH                             C.sub.6 H.sub.32,4(NO.sub.2).sub.2A-041  CH.sub.3 O          C      C.sub.6 H.sub.4 OCH.sub.3                             C.sub.6 H.sub.32,4(NO.sub.2).sub.2A-061  H       N      C.sub.6 H.sub.33,4-(OCH.sub.3).sub.2                             C.sub.6 H.sub.32,4(NO.sub.2).sub.2A-100  HO      C      C.sub.6 H.sub.4 OH                             C.sub.6 H.sub.44(NO.sub.2)A-111  HO      C      C.sub.6 H.sub.4 OH                             C.sub.6 H.sub.44(N.sub.3)______________________________________ 
    
     These compounds have a ring structure portion which steriochemically can occupy the estrogenic region of estrogen receptors, while the substituted phenyl arm steriochemically inhibits the receptor from undergoing an allosteric change to prevent translocation of estrogenic information to the nucleus. The electron rich density of the azido-, mono- and di-nitrophenyl and simple hydrazones provides sufficient electron density for long-lasting binding that permits less frequent administration of the drug while still achieving therapeutic objectives. 
     The novel compounds of the invention can be summarized as follows: ##STR2## 
     In preferred embodiments, a therapeutically effective amount of the compound is suspended in a pharmaceutically inert carrier such as peanut oil. In other embodiments, the compound can be made into a pill for oral administration. The compound could also be combined with an aqueous vehicle for injection. In other important embodiments the compound can be placed in solvents such as propylene glycol, dimethylsulfoxide (DMSO) or mixtures thereof and applied topically to tumor recurrences, such as occur with breast tumors after surgery. 
     The group of compounds described, in addition to their anti-estrogenic tumor activity, will inhibit estrogen interaction in the pituitary and thus stimulate the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH) resulting in ovulation. This is of importance in infertility problems, and the compound can accordingly be used to induce ovulation and permit conception to occur. The same dosages employed in connection with anti-tumor activity of the compound will be sufficient for use of the compound to induce ovulation. 
     In especially preferred embodiments of the compound, R is hydroxy, R 1  is hydroxyphenyl, and X is hydrogen. 
     In other preferred embodiments, R is hydrogen, hydroxy or methoxy; R 1  is carbon or nitrogen; R 2  is methyl, phenyl, hydroxyphenyl, or methoxyphenyl; and X is hydrogen. 
     Another preferred embodiment of the compound is formed when R is hydroxy, R 1  is carbon or nitrogen, R 2  is methyl, phenyl, hydroxyphenyl, methoxyphenyl, or dimethoxyphenyl and X is hydrogen, azidophenyl, aminophenyl, nitro or dinitrophenyl. 
     Another preferred embodiment is formed when R is hydrogen, hydroxy or methoxy; R 1  is nitrogen; R 2  is methyl, phenyl, hydroxyphenyl, or methoxyphenyl; X is hydrogen, azidophenyl, aminophenyl, nitro or dinitrophenyl. 
     Still another preferred embodiment is formed when R is hydrogen, hydroxy or methoxy; R 1  is carbon or nitrogen; R 2  is methyl, phenyl, hydroxyphenyl, or methoxyphenyl, and X is azidophenyl. 
     Yet another preferred embodiment is formed when R is hydrogen, hydroxy or methoxy; R 1  is carbon or nitrogen; R 2  is methyl, phenyl, hydroxyphenyl or methoxyphenyl; and X is aminophenyl. 
     A better understanding of these preferred embodiments can be had by reference to the following drawings and detailed description of how to make and use the instant invention. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS 
     FIG. 1 is a schematic view of an estrogen binding to an estrogen receptor before the receptor undergoes an allosteric change that permits translocation of the estrogen-receptor complex to the nucleus. 
     FIG. 2 is a view similar to FIG. 1 showing the receptor and estrogen after it has undergone an allosteric change and assumed the &#34;cocoon-like&#34; structure required for translocation of the complex to the nucleus. 
     FIG. 3 is a schematic view of the tamoxifen molecule bound to the protein receptor, the dimethyl-amino side chain preventing the receptor molecule from undergoing the allosteric change required for translocation to the nucleus. 
     FIG. 4 is a graph showing the uterotrophic activity and anti-uterotrophic activity of test compound A-033,  (biphenyl methylene-2,4-dinitrophenylhydrazone). For all graphs the upper line is for estradiol stimulation alone and represents the mean uterine net weight (60 mg) of the uterus of a rat which has received an injection of 0.64 ug of estradiol benzoate; the line below that represents the antiestrogenic effect of the compound; the next lower line represents the compound&#39;s estrogenic effects while the bottom line represents the control weight of an unstimulated uterus. 
     FIG. 5 is a graph similar to FIG. 4 showing the uterotrophic and anti-uterotrophic activitiy of compound A-041, (4,4&#39;-dimethoxy biphenyl methylene-2,4-dinitrophenylhydrazone). 
     FIG. 6 is a graph similar to FIG. 4 showing the uterotrophic and anti-uterotrophic activity of compound A-008, (4-hydroxyacetophenone-2,4-dinitrophenylhydrazone). 
     FIG. 7 is a graph showing the uterotrophic and antiuterotrophic activity of compound A-007, (4,4&#39;-dihydroxybiphenylmethylene-2,4-dinitrophenylhydrazone). 
     FIG. 8 is a graph showing the uterotrophic and antiuterotrophic activity of compound A-100 (4,4&#39;-dihydroxybiphenylmethylene-4-nitrophenylhydrazone). 
     FIG. 9 is a graph showing the uterotrophic and antiuterotrophic activity of compound A-111, (4,4&#39;-dihydroxybiphenylmethylene-4-azido-phenylhydrazone). 
     FIG. 10 is a bar graph showing colony formation of ZR-75-1 cells in soft agar for compounds A-007, A-008, A-100, A-111 and tamoxifen. 
    
    
     DETAILED DESCRIPTION 
     Molecular Structure 
     The following compounds have been synthesized, and their molecular structures are shown as follows: 
     4-Hydroxyacetophenone-2,4-dinitrophenylhydrazone (A-008) ##STR3## 
     Empirical formula C 14  H 12  N 4  O 5   
     Molecular weight: 316 
     Melting point: 240°-241° C. 
     solubility: Ethanol, methanol, acetone 
     Physical description: 
     Red crystals 
     Recrystallized from methanol/acetone 
     Anal. calc: C, 53.22; H, 3.87; N, 17.71, Found: C, 53.28; H, 3.82; N, 17.55. 
     Biphenyl methylene-2,4 dinitrophenylhydrazone (A-033) ##STR4## 
     Empirical formula: C 19  H 14  O 4  N 4   
     Molecular weight: 363 
     Melting point: 245° C. 
     Solubility: Conc. acetic acid, ethanol 
     Physical Description: Red Crystals 
     Anal. calc. C, 62.98; H, 3.86; N, 15.46, Found: C, 63.17; H, 4.06; N, 15.49. 
     4,4&#39;-Dihydroxybiphenyl-methylene-2,4-dinitrophenylhydrazone. (A-007) ##STR5## 
     Empirical formula: C 19  H 14  N 4  O 6   
     Molecular weight: 394 
     Melting point: 240°-241° C. 
     Soluble: Ethanol, methanol, acetone; insoluble in water 
     Physical description: 
     Red crystals 
     Recrystallized from ethanol 
     Anal calc.: C, 57.86; H, 3.55; N, 14.21, Found: C, 56.42; H, 3.81; N, 13.88. 
     4,4&#39;-Dimethoxy Diphenylmethylene-2,4-dinitrophenylhydrazone(A041) ##STR6## 
     Empirical formula: C 21  H 18  N 4  O 6   
     Molecular weight: 422 
     Melting Point: 205° C. 
     Solvent: Ethanol, methanol 
     Description: Red Needles 
     Anal. Calc. C, 59.71; H, 4.26; N, 13.27, Found: C, 59,85; H, 4.33; N, 13.36. 
     3,4-Dimethoxybenzyl-(2-piperidyl)-2,4-dinitrophenylhydrazone (A-061): ##STR7## 
     Empirical formula: C 20  H 17  O 6  N 5   
     Molecular weight: 423 
     Melting point: 230°-232° C. 
     Solubility: Methanol, water 
     Physical description: Fine orange powder 
     Anal calc: C, 56.7; H, 4.0; N, 16.5, Found: C, 56.5; H, 3.9; N, 16.7. 
     4-Methoxybenzyl-(2-piperidyl)-2,4-dinitrophenylhydrazone (A-077): ##STR8## 
     Empirical formula: C 19  H 15  N 5  O 5   
     Molecular weight: 393 
     Melting point: 230° C. 
     Solubility: Methanol, water 
     Physical description: Fine red powder 
     Anal. calc: C, 58.02; H, 3.82; N, 17.81, Found: C, 58.15; H, 3.77; N, 17.89. 
     4,4&#39;-Dihydroxybiphenyl-methylene-4-nitrophenylhydrazone (A-100). ##STR9## 
     Empirical formula C 19  H 15  N 3  O 4   
     Molecular weight: 349 
     Melting point: 245°-248° C. with dec. 
     Solubility: Ethanol, methanol, acetone; insoluble in water 
     Physical description: Red-Orange crystals Recrystallized from ethanol 
     Anal. calc: C, 65.33; H, 4.29,; N, 12.03, Found: C, 65.13; H, 4.19; N, 12.14. 
     4,4&#39;-Dihydroxybiphenyl-methylene-4-azidohydrazone (A-111). ##STR10## 
     Empirical formula: C 19  H 15  N 5  O 2   
     Molecular weight: 345 
     Melting point: 196°-197° 
     Solvent: Ethanol, methanol 
     Physical Description: Yellow amorphous powder 
     Anal. calc: C, 66.08; H, 4.35; N, 20.28, Found: C, 66.12; H, 4.42; N, 13.51. 
     4,4&#39;-Dihydroxybenzophenone Hydrazone (A-113) ##STR11## 
     Empirical formula: C 13  H 12  N 2  O 2   
     Molecular weight: 228 
     Melting point: 210°-215° 
     Solvent: Ethanol, methanol 
     Physical Description: Yellow crystals 
     Anal. calc: C, 66.42; H, 5.26; N, 12.28, Found: C, 68.37; H, 5.42; N, 12.24. 
     SYNTHESIS 
     Several groups of hydrazones have been synthesized and tested. Their synthesis is summarized in the table below. 
     The following ketone starting materials in Table 2 were obtained from Aldrich or Sigma Chemical Company: for A-008, 4-hydroxyacetophenone; for A-033, benzophenone; for A-007 &amp; A-100, 4,4&#39;-dihydroxybenzophenone; for A-041, 4,4&#39;dimethoxybenzophenone. Some phenylhydrazones which required synthesis or starting materials were for A-061, 3,4-dimethoxybenzyl (2-pyridyl) ketone; for A-077, 4-methoxybenzyl (2-pyridyl) ketone; and for A-111, 4,4&#39;dihydroxybiphenyl-methylene-4-azidohydrazone. The last three compounds were synthesized as below. 
     4-Methoxybenzyl(2-pyridyl) carbinol (for A-077) 
     Ketone starting material for A-077 was prepared from picolinic acid and 4-methoxybenzaldehyde. To a solution of 50 g. (0.37 moles) of 4-methoxybenzaldehyde and 50 ml. p-cymene (heated to dissolve) in a 3-neck flask with reflux condenser and refluxed until boiling, 10 g. (0.08 moles) picolinic acid was added dropwise and then refluxed for three hours. The solution changed in color from reddish to brown at the end. The solution was cooled and extracted in a separatory funnel with 2 N HCl (twice with 50 ml.). The above acid layer was washed twice with 100 ml. diethyl ether. The ether layer was discarded. The acid layer was basified with ice cold concentrated ammonium hydroxide at 0° C. The basic layer was extracted with diethyl ether (3×100 ml.) until clear. The ether washings were collected and dried over anhydrous sodium sulfate. The filtered ethereal solutions were evaporated (under roto-vacuum) at room temperature until an oil formed. The oil was dissolved in minimal ethanol to solubilize, and hot water dropwise was added until turbidity was produced and then disappeared on further heating. On cooling, a cloudy layer formed an oil which was removed by hand aspiration rapidly because it precipitated quickly. The 4-methoxybenzyl(2-pyridyl) carbinol oil was recrystallized from ethanol-water (80:20) as a white powder, 65% yield, mp 110°-112° C. Calc. for C 14  H 13  NO 2  : C, 74.01; H, 5.73; N, 6.16. Found: C, 74.09; H, 6.01; N, 6.04. 
     4-Methoxybenzyl(2-pyridyl) ketone (for A-077) 
     The carbinol, 10 g. (0.04 moles), synthesized in the above scheme, was dissolved in 200 ml. of water. To the solution, 5 g. of potassium permanganate in 200 ml. of water was slowly added with stirring maintaining the solution at 20° C. The solution was stirred for another 30 minutes. After the solution changed color, 30 ml. of ethanol were slowly added dropwise directly to the oxidized solution and stirred for an additional 10 minutes. The mixture was filtered until clear and evaporated to 75% of original volume under vacuum, and let stand in the cold. On standing, a white powder formed which recrystallized from methanol, mp 93°-94° C. Yield 36%. Anal. Calc. for C 14  H 11  N 1  O 2  : Calc. C, 69.13; H, 5.34; N, 5.76. Found, C, 68.92; H, 5.53; N, 5.60. 
     3,4-Dimethoxybenzyl (2-pyridyl) carbinol (for A-061) 
     Starting material for A-061 was prepared from picolinic acid and 3,4-dimethoxybenzaldehyde. To a solution of 50 g. (0.3 moles) of 3,4-dimethoxybenzaldehyde and 50 ml. p-cymene (heated to dissolve), 10 g. (0.08 moles) of picolinic acid was added dropwise at boiling reflux and then further refluxed for 3 hours. The solution became a reddish-brown at the end. The solution was cooled and extracted twice with 50 ml. of 2N HCL. The extracted layer was washed twice with 100 ml. of diethyl ether and the ether layer discarded. The acid layer was neutralized with ice cold concentrated ammonium hydroxide at 0° C. The neutralized layer was then extracted with diethyl ether (100 ml.×2) and the etheral layer saved and dried over anyhydrous sulfate. The ether layer was evaporated until an oil formed. The oil was dissolved in minimal ethanol-water, cooled, and in 1-4 days at 5° C., cream colored crystals formed; mp 93°-94° C. Yield: of 3,4-dimethoxybenzyl(2-pyridyl) carbinol was 30%. Anal. calc. for C 14  H 15  O 3  N 1  : Calc. C, 68.6; H, 6.11; N, 5.70. Found: C, 68.77, 6.29, and N, 5.68. 
     3,4 Dimethoxybenzyl(2-pyridyl) ketone 
     To 10 g. (0.04 moles) of the carbinol synthesized in the previous step, was added slowly with stirring, 5 g. of potassium permanganate in 200 ml. water at 20° C. The solution was stirred for another 30 minutes. After the color changed, 30 ml. of ethanol were added directly to the oxidized solution and stirred for an additional 10 minutes. The mixture was filtered until clear and evaporated to 75% of the original volume under vacuum and allowed to stand in the cold. On standing, a fine white powder formed which was recrystallized from aqueous ethanol, Yield: 65%; mp 93°-94° C. Calc. anal. for C 14  H 14  O 3  N 1  : Calc. C, 69.13; H, 5.34; N, 5.76. Found: C, 68.92; H, 5.53; and N, 5.60. 
     4,4&#39;-dihydroxybiphenyl-methylene-4-azidophenylhydrazone for (A-111) 
     Sodium hydrosulfite (8 g.) was added slowly under vigorous stirring to a refluxing solution of 1.12 g (0.0032 mole) of A-100 in 300 ml. of acetone, 60 ml. of water and 60 ml. of 1N sodium hydroxide. Refluxing was continued after the addition of sodium hydrosulfite was completed. The solution changed color from deep purple to deep orange in 30-40 minutes of stirring with reflux. To the solution 100 ml. of water was added. While still warm most of the acetone was removed under vacuum. The solution was neutralized with 10% acetic acid. After refrigeration overnight the reddish-orange precipitate was filtered, washed with cold water and dried. The crystals were recrystallized from 50% ethanol as orange needles (m.p. 172°-179°) of 4,4&#39;-dihydroxy biphenyl-methylene-4-amino phenylhydrazone. Yield was 400 mg. (37%). Anal for C 19  H 17  N 3  O 2  : Anal. calc: C, 68.89.; H, 5.14; N, 12.69. Found: C, 68.92; H,  5.61; N, 12.42. 
     The above amine (1.8 g., 0.0054 mole) was suspended in 8 ml. of 12N hydrochloric acid and cooled in a methanol-ice bath to -10° C. To this solution 0.6 g. of sodium nitrite (0.0087 mole) in 3 ml. of water was added slowly with stirring and not allowing the temperature to rise above 0° C. Then 8 ml. of cold (0° C.) glacial acetic acid was added after which 0.6 g. of sodium azide (0.0092  mole) in 2.5 ml. of water was added dropwise, with stirring, at a rate slow enough to keep the temperature below 10° C. All reactions subsequent to azide formation were carried out in vessels shielded from light. After the sodium azide was added, 15 ml. of cold water was added and the reaction mixture was stirred an additional 30 minutes. The product was a yellow-tan precipitate. The reaction mixture was then diluted to 100 ml. with cold water and the product removed by filtration. The product was washed with cold water and then air dried. The yield was 800 mg. (43%). The m.p. was 196°-197°. 
     Anal for C 19  H 15  N 5  O 2  : Calc. C, 66.08; H, 4.35; N, 20.28. Found: C, 66.12; H, 4.42; N, 13.51. 
     The following general procedures were employed for the synthesis of the phenylhydrazones: 
     
                       TABLE 2______________________________________STARTING MATERIALSCOMPOUNDS______________________________________A-008 4-hydroxyacetophenone                   2,4-dinitrophenylhydrazineA-033 benzophenone      2,4-dinitrophenylhydrazineA-007 4,4&#39;-dihydroxybenzophenone                   2,4-dinitropheylhydrazineA-100 4,4&#39;-dihydroxybenzophenone                   4-nitrophenylhydrazineA-041 4,4&#39;-dimethoxybenzophenone                   2,4-dinitrophenylhydrazineA-061 3,4-dimethoxybenzyl-                   2,4-dinitrophenylhydrazine (2-pyridyl)-ketoneA-077 4-methoxybenzyl   2,4-dinitrophenylhydrazine (2-pyridyl)-ketoneA-111 4,4&#39;-dihydroxybiphenyl- methylene-4-azidohydrazoneA-113 4,4&#39;-dihydroxybenzophenone                   hydrazine______________________________________ 
    
     Procedure 1: 
     4-Nitro- or 2,4-dinitrophenylhydrazine (0.0016 moles) was suspended in 5 ml. of methanol. The 4-nitrophenylhydrazine was used if the 4-nitrophenylhydrazone product was being prepared while the 2,4-dinitrophenylhydrazine was used if a 2,4-dinitrophenylhydrazone was being prepared. Dropwise, 0.4-0.5  ml. of concentrated sulfuric acid was cautiously added with stirring and the warm solution filtered. A solution of the carbonyl compound (0.0016 moles) in 5-20 ml. of methanol or ethanol was added dropwise to twice the above phenylhydrazine solution. If no solid separated from the reddish colored solution within 10 minutes, the solution was carefully diluted with 5-20 ml. of 2N sulfuric acid. The solid was collected by suction filtration and washed with a little cold methanol. The derivative was recrystallized from ethanol, methanol or dilute acetic acid according to Table 2. 
     Procedure 2: 
     4-Nitro- or 2,4-dinitrophenylhydrazine 2.5 g (0.016 moles) was dissolved in 30 ml. of 85 percent phosphoric acid. The solution was diluted with 20 ml. of 95 percent ethanol, allowed to stand and then filtered. 
     The carbonyl compound (0.008 moles) was dissolved in 10-40 ml. of ethanol and the calculated volume of the above reagent added, to produce a 2:1 rate of the 4-nitro- or 2,4-dinitrophenylhydrazine and ketone, respectively. If a precipitate did not form immediately, it ws diluted with a little water. The derivative was collected and recrystallized according to Table 2. 
     Hydrazone of 4,4&#39;-Dihydroxybenzophenone (A-113) 
     The method of synthesizing the hydrazone of 4,4&#39; dihydroxybenzophenone (A-113) required a slightly different synthesis as follows: a mixture of 10.4 g (0.08 mole) of hydrazine sulfate, 22 g (0.16 mole) of sodium acetate and 50 g of water is boiled five minutes, cooled to about 50° and 55 ml of methyl alcohol added. The precipitated sodium sulfate is filtered and washed with a little methanol. 
     A hot solution of 5.1 g (0.024 mole) of 4,4&#39;-dihydroxybenzophenone in 15 ml of methanol was added dropwise with stirring to the above solution of hydrazine at 60° C. 
     After the addition of the dihydroxybenzophenone, the yellow solution was refluxed with stirring for one hour. On cooling additional sodium sulfate precipitated and was filtered. Water was added slowly until turbid. On standing in a refrigerator over two days yellow crystals formed. Yield 72%, m.p. 210°-215°. Recrystallized from ethanol. 
     Anal. calc. for C 13  H 12  N 2  O 2  : C, 68.42; H, 5.26; N, 12.28. Found: C, 68.37; H, 5.42; N, 12.24. 
     ESTROGENIC-ANTIESTROGENIC ACTIVITIES 
     The discovery of estrogenic receptors in human breast cancer cells has provided a useful tool in determining the therapeutic utility of specific endocrine agents. The endocrine receptor assay is an extremely powerful tool for predicting the response to endocrine treatments since endrocrine receptors specifically concentrate estrogens into the target tissues. DeSombre et al., Steroid Receptors in Breast Cancer, New England J. of Med., 301: 1011-1012, 1979; J. H. Clark et al., Female Sex Steroids Receptors and Function, Monographs on Endocrinology, Vol. XIV, Berlin, Springer Verlag, 1979. 
     Estrogenic activity of the claimed compounds in the uterus was determined by employing the wet uterine weight of the immature (3-week-old) Sprague Dawley rat. Rats were sacrificed after three consecutive days of i.p. administration of test compounds at the specified doses. The mean control (unstimulated) uterine weight for a 21-day-old rat is 10 mg. Five to ten animals were employed at each dose level. The purpose of this test was to determine the estrogenic activity of each of the test compounds. Estrogenic activity can be determined by comparing the net uterine weight of the test animals to which the compounds were administered with the 10 mg. mean weight of rats not being injected with the drug. All drugs and estrogens were dissolved in peanut oil. 
     Antiestrogen activity in rat uterii was determined by giving 0.64 ug. of estradiol benzoate plus the test drug to immature Sprague Dawley rats at specified doses concomitantly i.p. for three days. Rats were sacrificed and uterii weighed. Estradiol benzoate alone produces a mean weight of 60 mg. in this system. Five to ten animals were employed at each dose level. 
     The data and graphs concerning uterotrophic activity demonstrate the relative activities of the test compounds in stimulating uterine growth. Such stimulation of uterine growth is a measurement of the test compounds&#39; estrogenic activity. Such activity is undesirable since it causes side effects and may satisfy the estrogenic requirements of estrogen dependent tumor cells. 
     The data and graphs concerning antiuterotrophic activity demonstrate the ability of the test compounds to inhibit stimulation of uterii which have been already stimulated by administration of 0.64 ug of estradiol benzoate to the test animal. A Sprague Dawley Rat receiving this dose of estradiol benzoate has a mean wet weight uterus of 60 mg. Percent inhibition of stimulation is measured by comparing the stimulated uterine weight (60 mg) with the uterine weight wherein estradiol benzoate and the test compound are administered concomitantly. 
     The data regarding estrogenic (or uterotrophic) activities and antiestrogenic (antiuterotrophic activities) for compounds A-008, 007, 033, 041, 061, 100, 111 and 113 in comparison to tamoxifen are shown in the following tables and FIGS. 4-9. 
     
         ______________________________________ANIMAL STUDIESTAMOXIFEN - CONTROLUTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________  UTEROTROPHIC ACTIVITYDrug Dose    --M wet wt. uterus                      Ratio(ug)     (mg)              Drug/Estradiol______________________________________1        23.               .344        25.1              .4216       29.2              .5864       --                .52128      17.1              .43256      25.5              .48512      21.2              --______________________________________  ANTI-UTEROTROPHIC ACTIVITY  (In the Presence of 60 ug of Estradiol Benzoate)Drug Dose    --M wet wt. uterus                      Percent(ug)     (mg)              Inhibition______________________________________1        40.3               04        35.3              1916       30.5              3764       30.3              38122      27.6              48256      21.6              71512      --                --______________________________________ --M Control  14 mg --M Estradiol  40 mg 
    
     
         ______________________________________A-008UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________  UTEROTROPHIC ACTIVITYDrug Dose    --M wet wt. uterus                      Ratio(ug)     (mg)              Drug/Estradiol______________________________________1        14                0.234        17                0.2816       12                0.2064       12                0.20128      13                0.22256      16                0.27512      25                0.42______________________________________  ANTI-UTEROTROPHIC ACTIVITY  (In the presence of 60 ug of Estradiol Benzoate)Drug Dose    --M wet wt. uterus                      Percent(ug)     (mg)              Inhibition______________________________________1        54                124        53                1416       50                2064       47                26128      28                64256      34                52512      30                60______________________________________ --M Control  10 mg --M Estradiol  60 mg 
    
     
         ______________________________________A-033UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________  UTEROTROPHIC ACTIVITYDrug Dose    --M wet wt. uterus                      Ratio(ug)     (mg)              Drug/Estradiol______________________________________1         8                0.134        10                0.1716       16                0.2764       17                0.28128      16                0.27256      17                0.28512      23                0.38______________________________________  ANTI-UTEROTROPHIC ACTIVITY  (In the Presence of 60 ug of Estradiol Benzoate)Drug Dose    --M wet wt. uterus                      Percent(ug)     (mg)              Inhibition______________________________________1        56                 84        50                2016       48                2464       50                20128      45                30256      44                50512      35                50______________________________________ --M Control  10 mg --M Estradiol  60 mg 
    
     
         ______________________________________A-007UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________  UTEROTROPHIC ACTIVITYDrug Dose    --M wet wt. uterus                      Ratio(ug)     (mg)              Drug/Estradiol______________________________________1        7                 0.124        7                 0.1216       9                 0.1564       8                 0.13128      14                0.23256      16                0.27512      15                0.25______________________________________  ANTI-UTEROTROPHIC ACTIVITY  (In the presence of 60 ug of Estradiol Benzoate)Drug Dose    --M wet wt. uterus                      Percent(ug)     (mg)              Inhibition______________________________________1        48                244        44                3216       41                3864       43                34128      42                36256      42                36512      32                56______________________________________ --M Control  10 mg --M Estradiol  60 mg 
    
     
         ______________________________________A-113UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________  UTEROTROPHIC ACTIVITYDrug Dose    --M wet wt. uterus                      Ratio(ug)     (mg)              Drug/Estradiol______________________________________1        7                 0.124        7                 0.1216       9                 0.1564       8                 0.13128      10                0.17256      14                0.23512      15                0.25______________________________________  ANTI-UTEROTROPHIC ACTIVITY  (In the presence of 60 ug of Estradiol Benzoate)Drug Dose    --M wet wt. uterus                      Percent(ug)     (mg)              Inhibition______________________________________1        48                244        44                3216       41                3864       43                34128      38                44256      39                42512      32                56______________________________________ --M Control  10 mg --M Estradiol  60 mg 
    
     
         ______________________________________A-041UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________  UTEROTROPHIC ACTIVITYDrug Dose    --M. wet wt. uterus                      Ratio(ug)     (mg)              Drug/Estradiol______________________________________1        11                0.184        13                0.2216       17                0.2864       16                0.27128      14                0.23256      15                0.25512      19                0.32______________________________________  ANTI-UTEROTROPHIC ACTIVITY  (In the presence of 60 ug of Estradiol Benzoate)Drug Dose    --M. wet wt. uterus                      Percent(ug)     (mg)              Inhibition______________________________________1        56                84        53                1416       56                864       58                4128      57                6256      53                14512      49                22______________________________________ --M Control  10 mg --M Estradiol  60 mg 
    
     
         ______________________________________A-061UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________  UTEROTROPHIC ACTIVITYDrug Dose    --M. wet wt. uterus                      Ratio(ug)     (mg)              Drug/Estradiol______________________________________1        21.3              0.284        19.7              0.2216       17.8              0.1564        9.3              0128      12.1              0256      12.5              0512      21.3              0.24______________________________________  ANTI-UTEROTROPHIC ACTIVITY  (In the presence of 60 ug of Estradiol Benzoate)Drug Dose    --M. wet wt. uterus                      Percent(ug)     (mg)              Inhibition______________________________________1        25.6              55.44        29.1              41.916       28.4              44.664       28.3              45.0128      25.0              57.7256      23.8              62.3512      25.8              54.6______________________________________ --M Control  14 mg --M Estradiol  40 mg 
    
     
         ______________________________________A-077UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________  UTEROTROPHIC ACTIVITYDrug Dose    --M. wet wt. uterus                      Ratio(ug)     (mg)              Drug/Estradiol______________________________________1        16.0              0.074        13.5              0.016       27.3              0.5164       33.9              0.76128      42.2              1.07256      36.0              0.84512      43.2              1.12______________________________________  ANTI-UTEROTROPHIC ACTIVITY  (In the presence of 60 ug of Estradiol Benzoate)Drug Dose    --M. wet wt. uterus                      Percent(ug)     (mg)              Inhibition______________________________________1        32.6              28.84        29.1              42.316       35.4              48.164       27.4              48.8128      31.1              34.6256      29.1              42.3512      24.7              59.2______________________________________ --M Control  14 mg --M Estradiol  40 mg 
    
     
         ______________________________________ANIMAL STUDIES (A-100)UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________    UTEROTROPHIC ACTIVITYDrug Dose  --M. wet wt. uterus                    Ratio(ug)       (mg)          Drug/Estradiol______________________________________1          6             0.104          10            0.1616         2             0.0364         14            0.23128        9             0.15256        10            0.16512        9             0.15______________________________________    ANTI-UTEROTROPHIC ACTIVITYDrug Dose  --M. wet wt. uterus                    Percent(ug)       (mg)          Inhibition______________________________________1          43            374          29            6716         28            6964         28            69128        27            71256        25            76512        28            69______________________________________ --M Control  14 mg --M Estradiol  60 mg 
    
     
         ______________________________________ANIMAL STUDIES (A-111)UTEROTROPHIC ACTIVITIES IN IMMATURE FEMALE(3-wk.old) SPRAGUE DAWLEY RATS______________________________________    UTEROTROPHIC ACTIVITYDrug Dose  --M. wet wt. uterus                    Ratio(ug)       (mg)          Drug/Estradiol______________________________________1          7             0.174          7             0.1716         9             0.1564         8             0.13128        17            0.28256        15            0.25512        9             0.15______________________________________    ANTI-UTEROTROPHIC ACTIVITYDrug Dose  --M. wet wt. uterus                    Percent(ug)       (mg)          Inhibition______________________________________1          48            244          40            4016         37            4364         38            44128        38            44256        41            38512        39            42______________________________________ --M Control  10 mg --M Estradiol  60 mg 
    
     COLONY FORMING ASSAY 
     Cell Culture and Growth Conditions 
     A soft-agar assay was used to investigate the influence of the synthesized agents on the colony formation of an estrogen dependent human breast carcinoma cell line-ZR-75-1 in culture. 
     An ER and PR positive human breast carcinoma cell line ZR-75-1 was obtained from the American Type Culture Collection (Rockville, MD), which was derived from a malignant ascitic effusion (Engel et al, 1978). The cells were grown as anchoring-dependent cultures in plastic flasks (FIG. 10), nourished with RPMI-1640 medium (GIBCO, Grand Island, NY) supplemented with 10-20% fetal calf serum (GIBCO) and antibiotics (100 U/ml penicillin; 100 ug/ml streptomycin). The flasks were incubated at 37° C. in a CO 2  incubator, the medium changed every 2-3 days, and the cells diluted by trypsinization at approaching confluency. Under experimental conditions these cells had a population doubling time of 94 hr. The saturation density was 1.92×10 8  cells/cm 2 . Cell counts and viability were determined with a hemacytometer and the trypan blue exclusion procedure. 
     Semi-confluent cultures of ZR-75-1 cells were removed from the culture flasks with a 0.05% trypsin/0.02% versene mixture (GIBCO), washed in Hanks&#39; balanced salt solution (GIBCO), and then resuspended in an enriched CMRL medium (GIBCO) containing supplements of nutrients and antibiotics as described by Hamburger and Salmon (1977) except that the spleen macrophage colony stimulating factor was not used, and that CaCl and DEAE-dextran were reduced to 1/10 and 1/5 of the quantities, respectively. Half of the cells was exposed to 3 log concentrations (0.01, 0.1 and 1.0 ug/ml) of tamoxifen (tamoxifen citrate, Stuart Pharmaceuticals, Wilmington, DE) at 37° C. for 1 hr. Under paired conditions, the other half of the cells was pre-incubated with 0.1 mM 17-beta-estradiol (Sigma Chemical Co., St. Louis, MO) for 30-60 min prior to exposure to Tamoxifen. 
     Identical procedures were used in which the test compounds A-007 through A-111 (Table 2) were added instead of the tamoxifen citrate to evaluate their cytotoxic responses. 
     After incubation with the drug, melted Bacto-agar (Difco Laboratories, Inc., Detroit, MI) was added to the cell suspension to a final concentration of 0.3% agar, and the mixture plated in a 35 mm plastic tissue culture dish on a feeder layer containing an enriched McCoy&#39;s 5A medium and 0.5% agar as described by Hamburger and Salmon (1977), except for the addition of 2-mercaptoethanol (5 mM) and the reduction of DEAE-dextran to 1/5 of the quantity. The seeding density for ZR-75-1 cells in this study was kept between 1-5×10 4  cells per dish and the plates incubated at 37° C. in a CO 2  incubator. Incubation was continued for another 3-4 weeks and the plates were examined under an inverted phase contrast microscope. Since these cells grew as tight aggregates in soft-agar, it was not possible to determine the number of cells in each growth. An ocular micrometer was instead used to count colonies 30 um or larger in size. Plating efficiency, defined as the number of colonies formed per 100 viable cells plated, was compared between groups. The effects of tamoxifen A-007-A-111 on the development of ZR-75-1 cells in soft-agar were measured as % of inhibition or % of stimulation of their dependent controls. The results are shown graphically in the drawings. 
     METHOD OF TREATMENT 
     Three of six cases treated with 4,4&#39; dihydroxyphenylbenzyl-4-nitrophenyl hydrazone (DPNH) are reviewed. 
     Case 1: 
     A 36 year old black female with advanced breast cancer developed a recurrence on her left chest wall at the site of her original mastectomy scar and in the field of previous irradiation. She did not have any other sites of involvement. She was treated with a 20% solution of 4,4&#39;-Dihydroxybenzophenone-4-nitrophenylhydrazone in propylene glycol-dimetylsulfoxide (DMSO): 50/50 ratio as a topical preparation. The solution was applied four times a day to the lesion and covered by gauze bandages. Over a four week period, the lesion underwent scar formation and healed completely. The area of original involvement was totally healed with no scarring after four months. The treatment was stopped after a total period of ten weeks. She was on no additional medication after that. 
     Case 2: 
     A 78 year old white female presented with advanced breast cancer spread to the chest wall just above the site of her mastectomy scar. Again, this site had been previously irradiated and grafted. Additional surgery and irradiation could not be offered. She was treated with a 20% solution of 4,4&#39;-Dihydroxybenzophenone-4-nitrophenylhydrazone in propylene glycol-dimethyl sulfoxide (DMSO): 50/50 ratio as a topical preparation. The solution was applied four times a day to the lesion and covered by gauge bandages. Over a two month period of daily applications, the lesion totally healed with granulation tissue formation and no cancer present. 
     Case 3: 
     A 84 year old white female with extensive skin metastasis from breast cancer was evaluated. The lesions were continuous over the right chest wall, back and abdomen. She had not responded to intravenous chemotherapy. She was treated with a 20% solution of 4,4&#39;-Dihydroxybenzophenone-4-nitrophenylhydrazone in propylene glycol-dimethylsulfoxide (DMSO): 50/50 ratio as a topical preparation, the solution was applied twice a day to the lesions and covered by gauze bandages. Over a three month period there was a 75% dissappearance of the lesions with healing. The patient remained in therapy. The chest wall was 75% clear with good skin healing. There was still 25% cancer involvement but the response was dramatic for such a large area.